Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma
Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.
You may also be interested in...
Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.
Ten Approvals To Look Out For In Q4
From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.
Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.